Trachoma cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Created page with "__NOTOC__ {{Trachoma}} {{CMG}} ==Cost-Effectiveness of Therapy== Globally, 84 million people suffer from active infection and nearly 8 million people are visually impaired as..." |
|||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ==Overview== | ||
Globally, 84 million people suffer from active infection and nearly 8 million people are visually impaired as a result of this disease. Globally this disease results in an estimated US $2.9 billion in lost productivity every year. | Globally, 84 million people suffer from active infection and nearly 8 million people are visually impaired as a result of this disease. Globally this disease results in an estimated US $2.9 billion in lost productivity every year. | ||
Revision as of 15:26, 12 December 2012
|
Trachoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Trachoma cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Trachoma cost-effectiveness of therapy |
|
Risk calculators and risk factors for Trachoma cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Globally, 84 million people suffer from active infection and nearly 8 million people are visually impaired as a result of this disease. Globally this disease results in an estimated US $2.9 billion in lost productivity every year.